Table 1.
Baseline characteristics
| Anti-acid medication at baseline | No anti-acid medication at baseline | |||
|---|---|---|---|---|
| Nintedanib (n = 244) | Placebo (n = 162) | Nintedanib (n = 394) | Placebo (n = 261) | |
| Age, years, mean (SD) | 67.4 (8.3) | 68.0 (7.4) | 66.1 (8.0) | 66.4 (8.1) |
| Male, n (%) | 179 (73.4) | 124 (76.5) | 328 (83.2) | 210 (80.5) |
| Race, n (%) | ||||
| White | 164 (67.2) | 117 (72.2) | 196 (49.7) | 131 (50.2) |
| Asian | 40 (16.4) | 28 (17.3) | 154 (39.1) | 100 (38.3) |
| Black | 0 (0.0) | 0 (0.0) | 2 (0.5) | 0 (0.0) |
| Missing* | 40 (16.4) | 17 (10.5) | 42 (10.7) | 30 (11.5) |
| Former or current smoker, n (%) | 170 (69.7) | 121 (74.7) | 294 (74.6) | 180 (69.0) |
| FVC, mL, mean (SD) | 2643 (712) | 2679 (818) | 2757 (781) | 2758 (806) |
| FVC, % predicted, mean (SD) | 80.3 (17.4) | 78.4 (17.3) | 79.4 (17.7) | 79.8 (18.8) |
| FEV1/FVC, %, mean (SD) | 82.0 (5.5) | 81.9 (5.9) | 81.4 (6.1) | 81.5 (6.0) |
| DLco, % predicted, mean (SD) | 47.6 (15.1) | 48.1 (14.3) | 47.3 (12.4) | 46.3 (12.8) |
| SGRQ total score, mean (SD)† | 43.4 (18.7) | 44.1 (17.9) | 37.2 (19.1) | 36.8 (18.4) |
*In France, regulation did not permit the collection of data on race. †n = 234 for nintedanib and n = 160 for placebo in anti-acid medication at baseline subgroup; n = 390 for nintedanib and n = 259 for placebo in no anti-acid medication at baseline subgroup